Oxygenta Pharmaceutical Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 105.52 million compared to INR 81.86 million a year ago. Revenue was INR 105.65 million compared to INR 81.87 million a year ago. Net income was INR 80.16 million compared to net loss of INR 42.91 million a year ago. Basic earnings per share from continuing operations was INR 2.55 compared to basic loss per share from continuing operations of INR 3.02 a year ago. Diluted earnings per share from continuing operations was INR 2.44 compared to diluted loss per share from continuing operations of INR 3.02 a year ago.
For the full year, sales was INR 396.42 million compared to INR 309.88 million a year ago. Revenue was INR 396.85 million compared to INR 310.05 million a year ago. Net loss was INR 34.79 million compared to INR 115.71 million a year ago. Basic loss per share from continuing operations was INR 1.09 compared to INR 8.15 a year ago. Diluted loss per share from continuing operations was INR 1.04 compared to INR 8.15 a year ago.